scholarly journals Riluzole exerts distinct antitumor effects from a metabotropic glutamate receptor 1-specific inhibitor on breast cancer cells

Oncotarget ◽  
2017 ◽  
Vol 8 (27) ◽  
pp. 44639-44653 ◽  
Author(s):  
Sonia C. Dolfi ◽  
Daniel J. Medina ◽  
Aparna Kareddula ◽  
Bhavna Paratala ◽  
Ashley Rose ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Cells ◽  
Glutamate Receptor ◽  
Breast Cancer Cells ◽  
Metabotropic Glutamate Receptor ◽  
Specific Inhibitor ◽  
Antitumor Effects ◽  
Metabotropic Glutamate ◽  
Metabotropic Glutamate Receptor 1

Riluzole mediates anti-tumor properties in breast cancer cells independent of metabotropic glutamate receptor-1

2016 ◽  
Vol 157 (2) ◽  
pp. 217-228 ◽  
Author(s):  
Cecilia L. Speyer ◽  
Mahdy A. Nassar ◽  
Ali H. Hachem ◽  
Miriam A. Bukhsh ◽  
Waris S. Jafry ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Cells ◽  
Glutamate Receptor ◽  
Breast Cancer Cells ◽  
Metabotropic Glutamate Receptor ◽  
Metabotropic Glutamate ◽  
Metabotropic Glutamate Receptor 1

scholarly journals Metabotropic glutamate receptor 1 is associated with unfavorable prognosis in ER-negative and triple-negative breast cancer

2020 ◽  
Vol 10 (1) ◽  
Author(s):  
Anna E. M. Bastiaansen ◽  
A. Mieke Timmermans ◽  
Marcel Smid ◽  
Carolien H. M. van Deurzen ◽  
Esther S. P. Hulsenboom ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Protein Expression ◽  
Glutamate Receptor ◽  
Triple Negative Breast Cancer ◽  
Triple Negative ◽  
Metabotropic Glutamate Receptor ◽  
Metabotropic Glutamate ◽  
Metabotropic Glutamate Receptor 1 ◽  
Novel Target ◽  
Cancer Tissues

AbstractNew therapies are an urgent medical need in all breast cancer subgroups. Metabotropic glutamate receptor 1 (mGluR1) is suggested as a potential new molecular target. We examined the prevalence mGluR1 expression in different clinically relevant breast cancer subgroups and determined its association with prognosis. In this retrospective cohort, 394 consecutive primary breast cancer tissues were incorporated into a tissue microarray and immunohistochemically stained for mGluR1. The prevalence of mGluR1 protein expression in different breast cancer subgroups was evaluated and correlated with metastasis-free survival (MFS) and overall survival (OS). In total, 56% (n = 219) breast cancer tissues had mGluR1 expression. In estrogen receptor (ER)-negative tumors, 31% (n = 18/58) had mGluR1 expression that was significantly associated with MFS (HR 5.00, 95% CI 1.03–24.35, p = 0.046) in multivariate analysis, independently from other prognostic factors. Of the 44 triple-negative breast cancer (TNBC), 25% (n = 11) expressed mGluR1. mGluR1 expression in TNBC was significantly associated with shorter MFS (HR 8.60, 95% CI 1.06–20.39, p = 0.044) and with poor OS (HR 16.07, 95% CI 1.16–223.10, p = 0.039). In conclusion, mGluR1 is frequently expressed in breast cancer. In ER-negative breast cancer and in TNBC mGluR1 protein expression is an unfavorable prognostic marker. This study provides rationale to explore mGluR1 as a novel target for breast cancer treatment, especially for the more aggressive TNBC.

scholarly journals Metabotropic Glutamate Receptor-1 Contributes to Progression in Triple Negative Breast Cancer

PLoS ONE ◽  
2014 ◽  
Vol 9 (1) ◽  
pp. e81126 ◽  
Author(s):  
Malathi Banda ◽  
Cecilia L. Speyer ◽  
Sara N. Semma ◽  
Kingsley O. Osuala ◽  
Nicole Kounalakis ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Glutamate Receptor ◽  
Triple Negative Breast Cancer ◽  
Triple Negative ◽  
Metabotropic Glutamate Receptor ◽  
Metabotropic Glutamate ◽  
Metabotropic Glutamate Receptor 1

scholarly journals Metabotropic glutamate receptor-1: a potential therapeutic target for the treatment of breast cancer

2011 ◽  
Vol 132 (2) ◽  
pp. 565-573 ◽  
Author(s):  
Cecilia L. Speyer ◽  
Jennifer S. Smith ◽  
Malathi Banda ◽  
John A. DeVries ◽  
Tassia Mekani ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Glutamate Receptor ◽  
Therapeutic Target ◽  
Metabotropic Glutamate Receptor ◽  
Potential Therapeutic Target ◽  
Metabotropic Glutamate ◽  
Metabotropic Glutamate Receptor 1

scholarly journals Metabotropic Glutamate Receptor 1 Expression and Its Polymorphic Variants Associate with Breast Cancer Phenotypes

PLoS ONE ◽  
2013 ◽  
Vol 8 (7) ◽  
pp. e69851 ◽  
Author(s):  
Madhura S. Mehta ◽  
Sonia C. Dolfi ◽  
Roman Bronfenbrener ◽  
Erhan Bilal ◽  
Chunxia Chen ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Glutamate Receptor ◽  
Metabotropic Glutamate Receptor ◽  
Metabotropic Glutamate ◽  
Metabotropic Glutamate Receptor 1 ◽  
Polymorphic Variants ◽  
Cancer Phenotypes

scholarly journals Metabotropic Glutamate Receptor-1 as a Novel Target for the Antiangiogenic Treatment of Breast Cancer

PLoS ONE ◽  
2014 ◽  
Vol 9 (3) ◽  
pp. e88830 ◽  
Author(s):  
Cecilia L. Speyer ◽  
Ali H. Hachem ◽  
Ali A. Assi ◽  
Jennifer S. Johnson ◽  
John A. DeVries ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Glutamate Receptor ◽  
Metabotropic Glutamate Receptor ◽  
Antiangiogenic Treatment ◽  
Metabotropic Glutamate ◽  
Metabotropic Glutamate Receptor 1 ◽  
Novel Target
Sign in / Sign up

Export Citation Format

Share Document